Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Manufacturing

Set Alert for Manufacturing

Procurement Must Look Beyond Price To Ensure Supply Chain Security

A globally co-ordinated approach to sourcing that rewards non-pricing criteria is imperative to bolster the security of the off-patent industry’s supply chain in the wake of the coronavirus pandemic, James Burt tells Generics Bulletin in the second part of our exclusive interview.

Pricing Strategies Manufacturing

European Industry Played Key Role In Mitigating COVID-19

In the first part of an exclusive two-part interview, James Burt – Accord’s executive vice-president for Europe, the Middle East and North Africa – talks to Generics Bulletin about the key actions taken by the generics industry to mitigate the coronavirus pandemic, and the changed landscape that the off-patent arena can expect to see in future.

Coronavirus COVID-19 Strategy

Kodak Establishes Pharmaceutical Unit To Tackle Shortages

Kodak’s new pharmaceutical unit receives a $765m loan from the US International Development Finance Corporation, through President Trump’s Defense Production Act, to produce critical pharma components that are essential but have lapsed into chronic national shortage, as defined by the FDA.

United States BioPharmaceutical

Industry Laments UK Change To SPC Waiver Approach

Changes to how the UK plans to implement the SPC manufacturing waiver after it separates itself fully from the EU following the current Brexit transition period have been criticized by the generics industry, while originators have welcomed the move.

Intellectual Property Manufacturing

Sandoz Strikes €150m Deal On Antibiotics In Austria

Sandoz has announced joint plans with the Austrian government to invest over €150m in antibiotics manufacturing.

Deals Manufacturing

India Promotes Domestic Manufacturing Of APIs To Become ‘Self-Reliant’

To ensure delivery of affordable healthcare to citizens, the Indian government’s department of pharmaceuticals has issued a notification highlighting the Production Linked Incentive Scheme that intends to boost domestic manufacturing of identified KSMs, intermediates and APIs by attracting large investments in the sector.

India Manufacturing
See All
UsernamePublicRestriction

Register